152 related articles for article (PubMed ID: 36159517)
21. Immune checkpoint inhibitor therapy for malignant pleural mesothelioma.
Nowak AK; Chin WL; Keam S; Cook A
Lung Cancer; 2021 Dec; 162():162-168. PubMed ID: 34823106
[TBL] [Abstract][Full Text] [Related]
22. Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma.
Cui W; Popat S
Drugs; 2021 Jun; 81(9):971-984. PubMed ID: 34106454
[TBL] [Abstract][Full Text] [Related]
23. Novel therapies for malignant pleural mesothelioma.
Scherpereel A; Wallyn F; Albelda SM; Munck C
Lancet Oncol; 2018 Mar; 19(3):e161-e172. PubMed ID: 29508763
[TBL] [Abstract][Full Text] [Related]
24. Zimberelimab plus chemotherapy as the first-line treatment of malignant peritoneal mesothelioma: A case report and review of literature.
Peng XD; You ZY; He LX; Deng Q
World J Clin Cases; 2023 Aug; 11(22):5296-5302. PubMed ID: 37621601
[TBL] [Abstract][Full Text] [Related]
25. Is there a role for immunotherapy in malignant pleural mesothelioma?
Tartarone A; Lerose R; Aieta M
Med Oncol; 2018 May; 35(7):98. PubMed ID: 29845408
[TBL] [Abstract][Full Text] [Related]
26. Nivolumab Immunotherapy in Malignant Mesothelioma: A Case Report Highlighting a New Opportunity for Exceptional Outcomes.
Jones RG; Karthik F; Dugar A; Kanagarajan K; Desai K; Bhandari M
Am J Case Rep; 2018 Jul; 19():783-789. PubMed ID: 29970876
[TBL] [Abstract][Full Text] [Related]
27. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Scherpereel A; Mazieres J; Greillier L; Lantuejoul S; Dô P; Bylicki O; Monnet I; Corre R; Audigier-Valette C; Locatelli-Sanchez M; Molinier O; Guisier F; Urban T; Ligeza-Poisson C; Planchard D; Amour E; Morin F; Moro-Sibilot D; Zalcman G;
Lancet Oncol; 2019 Feb; 20(2):239-253. PubMed ID: 30660609
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy for malignant pleural mesothelioma: current status and future directions.
Dozier J; Zheng H; Adusumilli PS
Transl Lung Cancer Res; 2017 Jun; 6(3):315-324. PubMed ID: 28713676
[TBL] [Abstract][Full Text] [Related]
29. Pemetrexed Maintenance Therapy Following Bevacizumab-Containing First-Line Chemotherapy in Advanced Malignant Pleural Mesothelioma: A Case Report and Literatures Review.
Jing XQ; Zhou L; Sun XD; Yu JM; Meng X
Medicine (Baltimore); 2016 Apr; 95(14):e3351. PubMed ID: 27057918
[TBL] [Abstract][Full Text] [Related]
30. Systemic treatment in patients with malignant pleural mesothelioma - real life experience.
Ziółkowska B; Cybulska-Stopa B; Papantoniou D; Suwiński R
BMC Cancer; 2022 Apr; 22(1):432. PubMed ID: 35443624
[TBL] [Abstract][Full Text] [Related]
31. Molecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP.
Dubois F; Bazille C; Levallet J; Maille E; Brosseau S; Madelaine J; Bergot E; Zalcman G; Levallet G
Target Oncol; 2022 Jul; 17(4):407-431. PubMed ID: 35906513
[TBL] [Abstract][Full Text] [Related]
32. The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.
Chen D; Li X; Zhao H; Fu Y; Yao F; Hu J; Du N
Indian J Cancer; 2014 Mar; 51 Suppl 3():e82-5. PubMed ID: 25818740
[TBL] [Abstract][Full Text] [Related]
33. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.
Disselhorst MJ; Quispel-Janssen J; Lalezari F; Monkhorst K; de Vries JF; van der Noort V; Harms E; Burgers S; Baas P
Lancet Respir Med; 2019 Mar; 7(3):260-270. PubMed ID: 30660511
[TBL] [Abstract][Full Text] [Related]
34. Malignant mediastinal mesothelioma treated with anlotinib: a case report and review of the literature.
Zhang Y; He W; Zhan K; Zhang L; Cao H; Xu R
Front Oncol; 2023; 13():1153233. PubMed ID: 37260970
[TBL] [Abstract][Full Text] [Related]
35. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.
Jackman DM; Kindler HL; Yeap BY; Fidias P; Salgia R; Lucca J; Morse LK; Ostler PA; Johnson BE; Jänne PA
Cancer; 2008 Aug; 113(4):808-14. PubMed ID: 18543326
[TBL] [Abstract][Full Text] [Related]
36. Treatment patterns and outcomes of patients with advanced malignant pleural mesothelioma in a community practice setting.
Waterhouse DM; Nwokeji ED; Boyd M; Penrod JR; Espirito JL; Robert NJ; Daumont MJ
Future Oncol; 2021 Jul; 17(19):2439-2448. PubMed ID: 33769073
[TBL] [Abstract][Full Text] [Related]
37. [How I manage... Malignant pleural mesothelioma in 2019].
Pellegrini I; Sibille A; Paulus A; Vaillant F; Radermecker MA; Corhay JL; Louis R; Duysinx B
Rev Med Liege; 2019 Dec; 74(12):627-632. PubMed ID: 31833271
[TBL] [Abstract][Full Text] [Related]
38. Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients.
Castagneto B; Zai S; Mutti L; Lazzaro A; Ridolfi R; Piccolini E; Ardizzoni A; Fumagalli L; Valsuani G; Botta M
Lung Cancer; 2001; 31(2-3):303-10. PubMed ID: 11165411
[TBL] [Abstract][Full Text] [Related]
39. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
Buikhuisen WA; Burgers JA; Vincent AD; Korse CM; van Klaveren RJ; Schramel FM; Pavlakis N; Nowak AK; Custers FL; Schouwink JH; Gans SJ; Groen HJ; Strankinga WF; Baas P
Lancet Oncol; 2013 May; 14(6):543-51. PubMed ID: 23583604
[TBL] [Abstract][Full Text] [Related]
40. EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study.
Zauderer MG; Szlosarek PW; Le Moulec S; Popat S; Taylor P; Planchard D; Scherpereel A; Koczywas M; Forster M; Cameron RB; Peikert T; Argon EK; Michaud NR; Szanto A; Yang J; Chen Y; Kansra V; Agarwal S; Fennell DA
Lancet Oncol; 2022 Jun; 23(6):758-767. PubMed ID: 35588752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
